<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03867253</url>
  </required_header>
  <id_info>
    <org_study_id>CL05-ORY-2001US</org_study_id>
    <nct_id>NCT03867253</nct_id>
  </id_info>
  <brief_title>Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease</brief_title>
  <acronym>ETHERAL-US</acronym>
  <official_title>A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oryzon Genomics S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer's Drug Discovery Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oryzon Genomics S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IIa study assessing the safety, tolerability and preliminary efficacy of&#xD;
      ORY-2001 in mild to moderate Alzheimer's Disease patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase IIa study is a double-blind, randomized, parallel-group and multicenter study with&#xD;
      a placebo-controlled 24-week treatment period followed by a no placebo-controlled 24-week&#xD;
      extension period.&#xD;
&#xD;
      It is planned to randomise 25 patients. In the double-blind placebo-controlled treatment&#xD;
      period, all patients will be randomized between two doses of ORY-2001 and placebo. In the&#xD;
      double-blind no placebo-controlled extension period, patients in the placebo arm will be&#xD;
      re-allocated in one of the two different dose levels of ORY-2001. Randomization will be&#xD;
      stratified by cognitive impairment severity.&#xD;
&#xD;
      An independent Data Monitoring Committee (DMC) will review un-blinded safety data throughout&#xD;
      the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 16, 2019</start_date>
  <completion_date type="Actual">November 12, 2020</completion_date>
  <primary_completion_date type="Actual">November 12, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>Week 24</time_frame>
    <description>Number, frequency and severity of Treatment Emergent Adverse Events (TEAEs) including serious TEAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>Week 48</time_frame>
    <description>Number, frequency and severity of Treatment Emergent Adverse Events (TEAEs) including serious TEAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Withdrawn patients due to TEAEs</measure>
    <time_frame>Week 24</time_frame>
    <description>Number and percentage of withdrawn patients due to TEAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Withdrawn patients due to TEAEs</measure>
    <time_frame>Week 48</time_frame>
    <description>Number and percentage of withdrawn patients due to TEAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohen-Mansfield Agitation Inventory (CMAI)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline to week 48 compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician version of the Apathy Evaluation Scale (AES-C)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline to week 48 compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>14-item Alzheimer's Disease Assessment Scale-Cognitive</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline to week 48 compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Computerized Cognitive Test battery</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline to week 48 compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State Examination (MMSE)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Dementia Rating Scale Sum of Boxes</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline to week 48 compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cornell Scale for Depression in Dementia (CSDD)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from baseline to week 48 compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Mild to Moderate Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>ORY-2001 Low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.6mg ORY-2001 capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ORY-2001 High dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.2mg ORY-2001 capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORY-2001 Low dose</intervention_name>
    <description>0.6mg ORY-2001 capsule</description>
    <arm_group_label>ORY-2001 Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORY-2001 High dose</intervention_name>
    <description>1.2mg ORY-2001 capsule</description>
    <arm_group_label>ORY-2001 High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Probable Alzheimer's Disease (AD) diagnosed according to National Institute of&#xD;
             Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and&#xD;
             Related Disorders Association (NINCDS-ADRDA) criteria&#xD;
&#xD;
          -  MMSE score at Screening and Baseline Visits of at least 16 and not greater than 26&#xD;
&#xD;
          -  Evidence of the AD pathophysiological process indicated by decreased levels of amyloid&#xD;
             antigen binding (AB) and increased levels of total Tau protein or phospho-Tau protein&#xD;
             in cerebrospinal fluid (CSF)&#xD;
&#xD;
          -  Outpatient consulting a general practitioner, or a&#xD;
             psychiatrist/neurologist/geriatrician&#xD;
&#xD;
          -  Knowledgeable and reliable close relative/caregiver who will accompany the patient to&#xD;
             all clinic visits during the study&#xD;
&#xD;
          -  Daily treatment with the same acetylcholinesterase inhibitor on a stable dose&#xD;
&#xD;
          -  Fertile male and female must use highly effective contraception, from the Screening&#xD;
             Visit until 90 days after last dose.&#xD;
&#xD;
          -  Signed informed consent by patient (or legal representative, if applicable) and a&#xD;
             close relative/caregiver prior to the initiation of any study specific procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to perform screening or baseline examinations&#xD;
&#xD;
          -  Hospitalization or change of concomitant medication 1 month prior to Screening visit&#xD;
             or during Screening Period&#xD;
&#xD;
          -  Clinical, laboratory or neuroimaging findings consistent with:&#xD;
&#xD;
               1. Other primary degenerative dementia;&#xD;
&#xD;
               2. Other neurodegenerative condition;&#xD;
&#xD;
               3. Cerebrovascular disease;&#xD;
&#xD;
               4. Other central nervous system diseases;&#xD;
&#xD;
          -  A current Diagnostic and Statistical Manual-5 (DSM-5) diagnosis of major depression,&#xD;
             schizophrenia or bipolar disorder&#xD;
&#xD;
          -  Positive results for tuberculosis, human immunodeficiency virus (HIV), hepatitis C or&#xD;
             hepatitis B (hepatitis B surface antigen [HbsAg]) serology at the Screening Visit&#xD;
&#xD;
          -  Clinically significant, advanced or unstable disease that may interfere with&#xD;
             evaluation.&#xD;
&#xD;
          -  Disability that may prevent the patients from completing all study requirements.&#xD;
&#xD;
          -  Chronic drug intake of forbidden concomitant medication.&#xD;
&#xD;
          -  Treatment with anti-amyloid beta or anti-Tau protein monoclonal antibodies or other&#xD;
             disease modifying strategies within three months or five half-lives, whichever is&#xD;
             longer, prior to the Screening Visit&#xD;
&#xD;
          -  Treatment with an active vaccine targeting amyloid beta or Tau protein&#xD;
&#xD;
          -  Suspected or known drug or alcohol abuse&#xD;
&#xD;
          -  Metallic implants or any other cause precluding the performance of brain MRI&#xD;
&#xD;
          -  Enrolment in another investigational study or intake of investigational drug within&#xD;
             the previous 3 months since the last dose&#xD;
&#xD;
          -  Suicide attempt within the last year or significant risk of suicide (in the opinion of&#xD;
             the investigator, defined as a &quot;yes&quot; to suicidal ideation questions 4 or 5, or&#xD;
             answering &quot;yes&quot; to suicidal behavior on the Columbia-Suicide Severity Rating Scale&#xD;
             within the past 12 months)&#xD;
&#xD;
          -  Any condition that in the opinion of the investigator makes the patient unsuitable for&#xD;
             inclusion in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Ropacki, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oryzon Genomics S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alzheimer's Research and Treatment Center</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Memory Center</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princeton Medical Institute</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associates Ltd.</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>191090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease, ORY-2001</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

